{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:58:15Z","timestamp":1785448695494,"version":"3.56.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Cancer Institute and the Fogarty International Center","award":["K01TW010271, T.A."],"award-info":[{"award-number":["K01TW010271, T.A."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10549-026-08022-3","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:09:44Z","timestamp":1783696184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of tumor-infiltrating lymphocytes and proinflammatory biomarkers with breast cancer molecular subtypes: analysis of the MEND study"],"prefix":"10.1007","volume":"218","author":[{"given":"Jovita","family":"Byemerwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Neish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukeman","family":"Forgah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Deveaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oyomoare","family":"Osazuwa-Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omolola","family":"Salako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adetola","family":"Daramola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olusegun","family":"Alatise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Ogun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adewale","family":"Adeniyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omobolaji","family":"Ayandipo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Olajide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olalekan","family":"Olasehinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olukayode","family":"Arowolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adewale","family":"Adisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oludolapo","family":"Afuwape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aralola","family":"Olusanya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aderemi","family":"Adegoke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trygve O.","family":"Tollefsbol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Arnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Muehlbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomi","family":"Akinyemiju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"8022_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S, Soerjomataram I (2022) Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast 66:15\u201323","journal-title":"Breast"},{"key":"8022_CR2","unstructured":"Fund WCR Breast Cancer Statistics n.d. April 15, 2025]; Available from: https:\/\/www.wcrf.org\/preventing-cancer\/cancer-statistics\/breast-cancer-statistics\/"},{"issue":"3","key":"8022_CR3","doi-asserted-by":"publisher","first-page":"e082492","DOI":"10.1136\/bmjopen-2023-082492","volume":"14","author":"KK Igbokwe","year":"2024","unstructured":"Igbokwe KK (2024) Comparative examination of breast cancer burden in sub-Saharan Africa, 1990\u20132019: estimates from Global Burden of Disease 2019 study. BMJ Open 14(3):e082492","journal-title":"BMJ Open"},{"issue":"4","key":"8022_CR4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nrc3896","volume":"15","author":"EC Dietze","year":"2015","unstructured":"Dietze EC, Sistrunk C, Miranda-Carboni G, O\u2019Regan R, Seewaldt VL (2015) Triple-negative breast cancer in African-American women: disparities versus biology. Nat Rev Cancer 15(4):248\u2013254","journal-title":"Nat Rev Cancer"},{"key":"8022_CR5","first-page":"347","volume":"2","author":"ID Gukas","year":"2008","unstructured":"Gukas ID, Girling AC, Mandong BM, Prime W, Jennings BA, Leinster SJ (2008) A comparison of clinicopathological features and molecular markers in british and nigerian women with breast cancer. Clin Med Oncol 2:347\u2013351","journal-title":"Clin Med Oncol"},{"issue":"12","key":"8022_CR6","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1093\/jnci\/djad154","volume":"115","author":"H Wang","year":"2023","unstructured":"Wang H, Ding X-H, Liu C-L, Xiao Y, Shui R-H, Li Y-P, Chen C, Yang W-T, Liu S, Chen C-S, Shao Z-M, Jiang Y-Z (2023) Genomic alterations affecting tumor-infiltrating lymphocytes and PD-L1 expression patterns in triple-negative breast cancer. JNCI: J Natl Cancer Inst 115(12):1586\u20131596","journal-title":"JNCI: J Natl Cancer Inst"},{"issue":"9","key":"8022_CR7","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R (2020) O\u2019Shaughnessy, Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med 382(9):810\u2013821","journal-title":"N Engl J Med"},{"issue":"22","key":"8022_CR8","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Di\u00e9ras V, Hegg R, Im S-A, Wright GS, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA (2018) Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 379(22):2108\u20132121","journal-title":"N Engl J Med"},{"key":"8022_CR9","doi-asserted-by":"publisher","first-page":"1266514","DOI":"10.3389\/fonc.2023.1266514","volume":"13","author":"E Olatunji","year":"2023","unstructured":"Olatunji E, Patel S, Graef K, Joseph A, Lasebikan N, Mallum A, Chigbo C, Jaffee E, Ngwa W (2023) Utilization of cancer immunotherapy in sub-Saharan Africa. Front Oncol 13:1266514","journal-title":"Front Oncol"},{"issue":"4","key":"8022_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nrclinonc.2015.215","volume":"13","author":"P Savas","year":"2016","unstructured":"Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, Loi S (2016) Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Reviews Clin Oncol 13(4):228\u2013241","journal-title":"Nat Reviews Clin Oncol"},{"key":"8022_CR11","doi-asserted-by":"publisher","first-page":"101134","DOI":"10.1016\/j.eclinm.2021.101134","volume":"41","author":"F Li","year":"2021","unstructured":"Li F, Li C, Cai X, Xie Z, Zhou L, Cheng B, Zhong R, Xiong S, Li J, Chen Z, Yu Z, He J, Liang W (2021) The association between CD8\u2009+\u2009tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis. EClinicalMedicine 41:101134","journal-title":"EClinicalMedicine"},{"issue":"1","key":"8022_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12885-020-6668-z","volume":"20","author":"G Gao","year":"2020","unstructured":"Gao G, Wang Z, Qu X, Zhang Z (2020) Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis. BMC Cancer 20(1):179","journal-title":"BMC Cancer"},{"issue":"13","key":"8022_CR13","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1001\/jama.2024.3056","volume":"331","author":"RA Leon-Ferre","year":"2024","unstructured":"Leon-Ferre RA, Jonas SF, Salgado R, Loi S, de Jong V, Carter JM, Nielsen TO, Leung S, Riaz N, Chia S, Jules-Cl\u00e9ment G, Curigliano G, Criscitiello C, Cockenpot V, Lambertini M, Suman VJ, Linderholm B, Martens JWM, van Deurzen CHM, Timmermans AM, Shimoi T, Yazaki S, Yoshida M, Kim SB, Lee HJ, Dieci MV, Bataillon G, Vincent-Salomon A, Andr\u00e9 F, Kok M, Linn SC, Goetz MP, Michiels S (2024) Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. JAMA 331(13):1135\u20131144","journal-title":"JAMA"},{"key":"8022_CR14","doi-asserted-by":"crossref","unstructured":"Ciarka A, Pi\u0105tek M, P\u0119ksa R, Kunc M, Senkus E (2024) Tumor-Infiltrating Lymphocytes (TILs) in breast cancer: prognostic and predictive significance across molecular subtypes. Biomedicines 12(4)","DOI":"10.3390\/biomedicines12040763"},{"issue":"13","key":"8022_CR15","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1001\/jama.2024.3056","volume":"331","author":"RA Leon-Ferre","year":"2024","unstructured":"Leon-Ferre RA, Jonas SF, Salgado R, Loi S, de Jong V, Carter JM, Nielsen TO, Leung S, Riaz N, Chia S, Jules-Cl\u00e9ment G, Curigliano G, Criscitiello C, Cockenpot V, Lambertini M, Suman VJ, Linderholm B, Martens JWM, van Deurzen CHM, Timmermans AM, Shimoi T, Yazaki S, Yoshida M, Kim S-B, Lee HJ, Dieci MV, Bataillon G, Vincent-Salomon A, Andr\u00e9 F, Kok M, Linn SC, Goetz MP, Michiels S (2024) International Immuno-Oncology Biomarker Working, Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. JAMA 331(13):1135\u20131144","journal-title":"JAMA"},{"issue":"1","key":"8022_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten FR, Grivennikov SI (2019) Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity 51(1):27\u201341","journal-title":"Immunity"},{"key":"8022_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-1-60761-401-2_5","volume":"598","author":"DR Germolec","year":"2010","unstructured":"Germolec DR, Frawley RP, Evans E (2010) Markers of inflammation. Methods Mol Biol 598:53\u201373","journal-title":"Methods Mol Biol"},{"issue":"3","key":"8022_CR18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.17219\/acem\/62120","volume":"26","author":"Y Ma","year":"2017","unstructured":"Ma Y, Ren Y, Dai ZJ, Wu CJ, Ji YH, Xu J (2017) IL-6, IL-8 and TNF-\u03b1 levels correlate with disease stage in breast cancer patients. Adv Clin Exp Med 26(3):421\u2013426","journal-title":"Adv Clin Exp Med"},{"issue":"1","key":"8022_CR19","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","volume":"9","author":"M Yi","year":"2024","unstructured":"Yi M, Li T, Niu M, Zhang H, Wu Y, Wu K, Dai Z (2024) Targeting cytokine and chemokine signaling pathways for cancer therapy. Signal Transduct Target Therapy 9(1):176","journal-title":"Signal Transduct Target Therapy"},{"key":"8022_CR20","doi-asserted-by":"crossref","unstructured":"Jang DI, Lee AH, Shin HY, Song HR, Park JH, Kang TB, Lee SR, Yang SH (2021) The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics. Int J Mol Sci 22(5)","DOI":"10.3390\/ijms22052719"},{"issue":"2","key":"8022_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.14740\/wjon2532","volume":"16","author":"N Qodir","year":"2025","unstructured":"Qodir N, Pramudhito D, Hafy Z, Iman MB, Syafira F, Afladhanti PM, Daenasa RS, Indra B (2025) Tumor Necrosis Factor-Alpha and Its Association With Breast Cancer: A Systematic Review. World J Oncol 16(2):143\u2013151","journal-title":"World J Oncol"},{"key":"8022_CR22","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3389\/fonc.2020.00584","volume":"10","author":"MF Mercogliano","year":"2020","unstructured":"Mercogliano MF, Bruni S, Elizalde PV, Schillaci R (2020) Tumor Necrosis Factor \u03b1 Blockade: An Opportunity to Tackle Breast Cancer. Front Oncol 10:584","journal-title":"Front Oncol"},{"key":"8022_CR23","first-page":"1","volume":"5","author":"T Akinyemiju","year":"2019","unstructured":"Akinyemiju T, Salako O, Daramola A, Alatise O, Adeniyi A, Ogun G, Ayandipo O, Olajide T, Olasehinde O, Arowolo O, Adisa A, Afuwape O, Olusanya A, Adegoke A, Ojo A, Tollefsbol T, Arnett D (2019) Collaborative Molecular Epidemiology Study of Metabolic Dysregulation, DNA Methylation, and Breast Cancer Risk Among Nigerian Women: MEND Study Objectives and Design. J Glob Oncol 5:1\u20139","journal-title":"J Glob Oncol"},{"issue":"1","key":"8022_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/jbi\/wbaa110","volume":"3","author":"KS Johnson","year":"2020","unstructured":"Johnson KS, Conant EF, Soo MS (2020) Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists. J Breast Imaging 3(1):12\u201324","journal-title":"J Breast Imaging"},{"issue":"7","key":"8022_CR25","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3390\/cancers17071102","volume":"17","author":"E Carvalho","year":"2025","unstructured":"Carvalho E, Canberk S, Schmitt F, Vale N (2025) Molecular Subtypes and Mechanisms of Breast Cancer: Precision Medicine Approaches for Targeted Therapies. Cancers 17(7):1102","journal-title":"Cancers"},{"issue":"2","key":"8022_CR26","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26(2):259\u2013271","journal-title":"Ann Oncol"},{"key":"8022_CR27","doi-asserted-by":"crossref","unstructured":"Fuchs TL, Sioson L, Sheen A, Jafari-Nejad K, Renaud CJ, Andrici J, Ahadi M, Chou A, Gill AJ (2020) Assessment of tumor-infiltrating lymphocytes using international TILs Working Group (ITWG) system is a strong predictor of overall survival in colorectal carcinoma: a study of 1034 patients. Am J Surg Pathol 44(4)","DOI":"10.1097\/PAS.0000000000001409"},{"issue":"19","key":"8022_CR28","doi-asserted-by":"publisher","first-page":"4844","DOI":"10.3390\/cancers14194844","volume":"14","author":"J Pousette","year":"2022","unstructured":"Pousette J, Johansson A, J\u00f6nsson C, Fornander T, Lindstr\u00f6m LS, Olsson H (2022) Perez-Tenorio, Prognostic and Predictive Significance of Stromal Tumor-Infiltrating Lymphocytes (sTILs) in ER-Positive\/HER2\u2009\u2013\u2009Negative Postmenopausal Breast Cancer Patients. Cancers 14(19):4844","journal-title":"Cancers"},{"key":"8022_CR29","doi-asserted-by":"crossref","unstructured":"K\u0131n\u0131ko\u011flu O, Alt\u0131nta\u015f YE, Y\u0131ld\u0131z A, Akda\u011f G, Bal H, Ya\u015far ZY, \u00d6zkerim U, Y\u0131ld\u0131z H, \u00d6ks\u00fcz S, T\u00fcnbekici S, Do\u011fan A, I\u015f\u0131k D, Ya\u015far A, Ba\u015fo\u011flu T, S\u00fcrmeli H, Odaba\u015f H, Turan N (2025) Tumor-infiltrating lymphocytes as predictive biomarkers in neoadjuvant treatment of HER2-positive breast cancer. Oncologist 30(4)","DOI":"10.1093\/oncolo\/oyaf054"},{"issue":"12Supplement","key":"8022_CR30","first-page":"P1","volume":"31","author":"P Krivorotko","year":"2025","unstructured":"Krivorotko P, Abdullaeva S, Semiglazova T, Artemyeva A, Kudaybergenova A, Zagoruiko V, Kudriashova T, Ponasenko O, Semiglazov V, Semiglazov V (2025) Abstract P1-06-26: The optimal cut-off point for Tumor-Infiltrating Lymphocytes (TILs) in Triple-Negative Breast Cancer (TNBC). Clin Cancer Res 31(12Supplement):P1\u201306","journal-title":"Clin Cancer Res"},{"key":"8022_CR31","doi-asserted-by":"crossref","unstructured":"Dingle K, Azizieh F (2019) Multivariate comparison of cytokine profiles for normal- and low-bone-density subjects. Diagnostics (Basel) 9(4)","DOI":"10.3390\/diagnostics9040134"},{"key":"8022_CR32","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3389\/fpubh.2016.00216","volume":"4","author":"A Tsurumi","year":"2016","unstructured":"Tsurumi A, Que YA, Ryan CM, Tompkins RG, Rahme LG (2016) TNF-\u03b1\/IL-10 Ratio Correlates with Burn Severity and May Serve as a Risk Predictor of Increased Susceptibility to Infections. Front Public Health 4:216","journal-title":"Front Public Health"},{"key":"8022_CR33","doi-asserted-by":"crossref","unstructured":"Hong CC, Yao S, McCann SE, Dolnick RY, Wallace PK, Gong Z, Quan L, Lee KP, Evans SS, Repasky EA, Edge SB, Ambrosone CB (2013) Pretreatment levels of circulating Th1 and Th2 cytokines, and their ratios, are associated with ER-negative and triple negative breast cancers. Breast Cancer Res Treat 139(2):477\u2009\u2013\u200988","DOI":"10.1007\/s10549-013-2549-3"},{"key":"8022_CR34","doi-asserted-by":"crossref","unstructured":"Kehm RD, McDonald JA, Fenton SE, Kavanaugh-Lynch M, Leung KA, McKenzie KE, Mandelblatt JS, Terry MB (2020) Inflammatory biomarkers and breast cancer risk: a systematic review of the evidence and future potential for intervention research. Int J Environ Res Public Health 17(15)","DOI":"10.3390\/ijerph17155445"},{"issue":"9","key":"8022_CR35","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.2174\/138945010792006799","volume":"11","author":"JE Goldberg","year":"2010","unstructured":"Goldberg JE, Schwertfeger KL (2010) Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets 11(9):1133\u20131146","journal-title":"Curr Drug Targets"},{"issue":"1","key":"8022_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/jir.2014.0026","volume":"35","author":"M Esquivel-Vel\u00e1zquez","year":"2015","unstructured":"Esquivel-Vel\u00e1zquez M, Ostoa-Saloma P, Palacios-Arreola MI, Nava-Castro KE, Castro JI, Morales-Montor J (2015) The role of cytokines in breast cancer development and progression. J Interferon Cytokine Res 35(1):1\u201316","journal-title":"J Interferon Cytokine Res"},{"key":"8022_CR37","unstructured":"R Core Team (2022) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/"},{"issue":"10","key":"8022_CR38","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1001\/jamaoncol.2016.1061","volume":"2","author":"SE Stanton","year":"2016","unstructured":"Stanton SE, Adams S, Disis ML (2016) Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review. JAMA Oncol 2(10):1354\u20131360","journal-title":"JAMA Oncol"},{"issue":"2","key":"8022_CR39","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10549-023-06921-3","volume":"199","author":"S Sayed","year":"2023","unstructured":"Sayed S, Koka H, Abubakar M, Gardner K, Salgado R, Moloo Z, B Caban-Ure\u00f1a A, Rosen D, Castro P, Saleh M, J Shaikh A, Shah J, Figueroa J, Makokha F, K Ha H, Wang Z, Magangane P, Naidoo R, Ngundo V, R Yang X, Govender D (2023) Tumour Infiltrating Lymphocytes (TILs) and immune composition in breast cancer patients from Kenya: Spatial distributions and associations with risk factors and tumour characteristics. Breast Cancer Res Treat 199(2):401\u2013413","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"8022_CR40","doi-asserted-by":"publisher","first-page":"e0224760","DOI":"10.1371\/journal.pone.0224760","volume":"14","author":"A Mremi","year":"2019","unstructured":"Mremi A, Broadwater G, Jackson K, Amsi P, Mbulwa C, Hyslop T, Ong C, Hall A (2019) Breast cancer in Tanzanian, black American, and white American women: An assessment of prognostic and predictive features, including tumor infiltrating lymphocytes. PLoS ONE 14(11):e0224760","journal-title":"PLoS ONE"},{"issue":"8","key":"8022_CR41","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/jnci\/djaa215","volume":"113","author":"S Yao","year":"2021","unstructured":"Yao S, Cheng TD, Elkhanany A, Yan L, Omilian A, Abrams SI, Evans S, Hong CC, Qi Q, Davis W, Liu S, Bandera EV, Odunsi K, Takabe K, Khoury T, Ambrosone CB (2021) Breast Tumor Microenvironment in Black Women: A Distinct Signature of CD8\u2009+\u2009T-Cell Exhaustion. J Natl Cancer Inst 113(8):1036\u20131043","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"8022_CR42","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.annonc.2021.07.007","volume":"32","author":"S Loi","year":"2021","unstructured":"Loi S, Michiels S, Adams S, Loibl S, Budczies J, Denkert C, Salgado R (2021) The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. Ann Oncol 32(10):1236\u20131244","journal-title":"Ann Oncol"},{"issue":"5","key":"8022_CR43","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1101\/gr.165985.113","volume":"24","author":"SD Brown","year":"2014","unstructured":"Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, Holt RA (2014) Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 24(5):743\u2013750","journal-title":"Genome Res"},{"issue":"7471","key":"8022_CR44","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MDM, Miller CA, Welch JS, Walter MJ, Wendl MC, Ley TJ, Wilson RK, Raphael BJ, Ding L (2013) Mutational landscape and significance across 12 major cancer types. Nature 502(7471):333\u2013339","journal-title":"Nature"},{"issue":"10","key":"8022_CR45","doi-asserted-by":"publisher","first-page":"e1490854","DOI":"10.1080\/2162402X.2018.1490854","volume":"7","author":"A Thomas","year":"2018","unstructured":"Thomas A, Routh ED, Pullikuth A, Jin G, Su J, Chou JW, Hoadley KA, Print C, Knowlton N, Black MA, Demaria S, Wang E, Bedognetti D, Jones WD, Mehta GA, Gatza ML, Perou CM, Page DB, Triozzi P, Miller LD (2018) Tumor mutational burden is a determinant of immune-mediated survival in breast cancer. Oncoimmunology 7(10):e1490854","journal-title":"Oncoimmunology"},{"key":"8022_CR46","doi-asserted-by":"crossref","unstructured":"El Bairi, K., H.R. Haynes, E. Blackley, S. Fineberg, J. Shear, S. Turner, J.R. de Freitas, D. Sur, L.C. Amendola, M. Gharib, A. Kallala, I. Arun, F. Azmoudeh-Ardalan,L. Fujimoto, L.F. Sua, S.-W. Liu, H.-C. Lien, P. Kirtani, M. Balancin, H. El Attar,P. Guleria, W. Yang, E. Shash, I.C. Chen, V. Bautista, J.F. Do Prado Moura, B.L. Rapoport,C. Castaneda, E. Spengler, G. Acosta-Haab, I. Frahm, J. Sanchez, M. Castillo, N. Bouchmaa,R.R. Md Zin, R. Shui, T. Onyuma, W. Yang, Z. Husain, K. Willard-Gallo, A. Coosemans,E.A. Perez, E. Provenzano, P.G. Ericsson, E. Richardet, R. Mehrotra, S. Sarancone,A. Ehinger, D.L. Rimm, J.M.S. Bartlett, G. Viale, C. Denkert, A.I. Hida, C. Sotiriou,S. Loibl, S.M. Hewitt, S. Badve, W.F. Symmans, R.S. Kim, G. Pruneri, S. Goel, P.A.Francis, G. Inurrigarro, R. Yamaguchi, H. Garcia-Rivello, H. Horlings, S. Afqir, R.Salgado, S. Adams, M. Kok, M.V. Dieci, S. Michiels, S. Demaria, S. Loi, K. El Bairi,H.R. Haynes, E. Blackley, S. Fineberg, J. Shear, S. Turner, J.R. de Freitas, D. Sur,L.C. Amendola, M. Gharib, A. Kallala, I. Arun, F. Azmoudeh-Ardalan, L. Fujimoto, L.F.Sua, S.-W. Liu, H.-C. Lien, P. Kirtani, M. Balancin, H. El Attar, P. Guleria, W. Yang,E. Shash, I.C. Chen, V. Bautista, J.F. Do Prado Moura, B.L. Rapoport, C. Castaneda,E. Spengler, G. Acosta-Haab, I. Frahm, J. Sanchez, M. Castillo, N. Bouchmaa, R.R.Md Zin, R. Shui, T. Onyuma, W. Yang, Z. Husain, K. Willard-Gallo, A. Coosemans, E.A.Perez, E. Provenzano, P.G. Ericsson, E. Richardet, R. Mehrotra, S. Sarancone, A. Ehinger,D.L. Rimm, J.M.S. Bartlett, G. Viale, C. Denkert, A.I. Hida, C. Sotiriou, S. Loibl,S.M. Hewitt, S. Badve, W.F. Symmans, R.S. Kim, G. Pruneri, S. Goel, P.A. Francis,G. Inurrigarro, R. Yamaguchi, H. Garcia-Rivello, H. Horlings, S. Afqir, R. Salgado,S. Adams, M. Kok, M.V. Dieci, S. Michiels, S. Demaria, S. Loi, V. Schelfhout, E. Arbzadeh,A. Bondanar, S.A.G. Reyes, J.R. Ruz, J. Kang, L. Xiang, M. Zimovjanova, P. Togores,T. Ozturk, A. Patil, M. Corpa, A. Whitehouse, B. Tan, A. de Paula, C. Rossetti, C.Lang-Schwarz, S. Mahon, C. Giacometti, B. Linderholm, F. Deman, G. Montagna, G. Gong,M. Pavcovich, Y. Chaer, I.A. Cabrero, M.L. de Brito, N. Ilieva, A. Fulop, M. Souza,D. Bilancia, M. Idowu, R. Johri, J. Szpor, L. Bachani, F. Schmitt, M. Giannotti, Y.Kurebayashi, B.E.A. Ramirez, E. Salido, L. Bortesi, S. Bonetto, K. Elomina, P. Lopez,V. Sharma, A. Edirisinghe, D. Mathur, A. Sahay, M.A. Mouloud, C.H. Giang, E. Mukolwe,E. Kiruka, N. Samberg, N. Abe, M. Brown, E. Millar, X. Li, Z. Yuan, A. Pasupathy,R. Miele, R. Luff, M.M.A. e Porfirio, O. Ajemba, R. Soni, E. Orvieto, M. DiMaio, J.Thomas, R. Merard, M.M. Subramaniam, T. Apolinario, O. Preda, R. Preda, A. Makanga,M.S. Maior, L. Li, M. Saghatchian, T. Saurine, E. Janssen, J. Cochran, N. Vlada, R.Cappellesso, K. Elfer, M. Hollick, S. Desai, G. Oner, A. Schreurs, S. Liu, R. Perera,P. Mercurio, F. Garcia, K. Hosny, H. Matsumoto, C. van Deurzen, G. Bianchini, I. Coban,A. Jahangir, A. Rahman, D. Stover, P. Luz, A. Martel, Y. Waumans, A. Stenzinger, J.Cortes, P. Dimitrova, I. Nauwelaers, M. Velasco, F. Fan, G. Akturk, M. Firer, I. Roxanis,M. Schneck, H. Wen, V. Cockenpot, A. Konstantinov, A. Calatrava, M.N. Vidya, H.J.Choi, P. Jank, A.H. \u00c7\u00cfinen, D. Sabanathan, G. Floris, D. Hoeflmayer, T. Hamada, N.Laudus, A. Grigoriadis, I. Porcellato, B. Acs, F. Miglietta, J. Parrodi, D. Clunie,B. Calhoun, F.-I. Lu, A. Lefevre, S. Tabbarah, W. Tran, I. Garcia-murillas, P. Jelinic,C. Boeckx, S. Souza, M. Cebollero, E. Felip, J.L.S. Rendon, E. El Gabry, J. Saltz,E. Bria, G. Garufi, J. Hartman, M. Sebastian, H. Olofsson, L. Kooreman, J. Cucherousset and G (2021) The International Immuno-Oncology Biomarker Working, The tale of TILs in breast cancer: a report from the international immuno-oncology biomarker working group. npj Breast Cancer 7(1):150","DOI":"10.1038\/s41523-021-00346-1"},{"issue":"1","key":"8022_CR47","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40425-019-0548-6","volume":"7","author":"G Griguolo","year":"2019","unstructured":"Griguolo G, Pascual T, Dieci MV, Guarneri V, Prat A (2019) Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer. J Immunother Cancer 7(1):90","journal-title":"J Immunother Cancer"},{"issue":"1","key":"8022_CR48","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1210\/endrev\/bnac017","volume":"44","author":"B Chakraborty","year":"2022","unstructured":"Chakraborty B, Byemerwa J, Krebs T, Lim F, Chang C-Y, McDonnell DP (2022) Estrogen Receptor Signaling in the Immune System. Endocr Rev 44(1):117\u2013141","journal-title":"Endocr Rev"},{"issue":"39","key":"8022_CR49","doi-asserted-by":"publisher","first-page":"eadp2442","DOI":"10.1126\/sciadv.adp2442","volume":"10","author":"S Artham","year":"2024","unstructured":"Artham S, Juras PK, Goyal A, Chakraborty P, Byemerwa J, Liu S, Wardell SE, Chakraborty B, Crowder D, Lim F, Strawser CH, Newlin M, Racioppi A, Dent S, Mirminachi B, Roper J, Perou CM, Chang CY, McDonnell DP (2024) Estrogen signaling suppresses tumor-associated tissue eosinophilia to promote breast tumor growth. Sci Adv 10(39):eadp2442","journal-title":"Sci Adv"},{"key":"8022_CR50","doi-asserted-by":"crossref","unstructured":"Chakraborty B, Byemerwa J, Shepherd J, Haines CN, Baldi R, Gong W, Liu W, Mukherjee D, Artham S, Lim F, Bae Y, Brueckner O, Tavares K, Wardell SE, Hanks BA, Perou CM, Chang CY, McDonnell DP (2021) Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma. J Clin Invest 131(23).","DOI":"10.1172\/JCI151347"},{"issue":"1","key":"8022_CR51","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1158\/2159-8290.CD-16-0502","volume":"7","author":"N Svoronos","year":"2017","unstructured":"Svoronos N, Perales-Puchalt A, Allegrezza MJ, Rutkowski MR, Payne KK, Tesone AJ, Nguyen JM, Curiel TJ, Cadungog MG, Singhal S, Eruslanov EB, Zhang P, Tchou J, Zhang R (2017) Conejo-Garcia, Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells. Cancer Discov 7(1):72\u201385","journal-title":"Cancer Discov"},{"key":"8022_CR52","doi-asserted-by":"publisher","first-page":"104295","DOI":"10.1016\/j.jri.2024.104295","volume":"165","author":"H Alanazi","year":"2024","unstructured":"Alanazi H, Zhang Y, Fatunbi J, Luu T, Kwak-Kim J (2024) The impact of reproductive hormones on T cell immunity; normal and assisted reproductive cycles. J Reprod Immunol 165:104295","journal-title":"J Reprod Immunol"},{"issue":"2","key":"8022_CR53","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/jcp.21221","volume":"214","author":"P Tai","year":"2008","unstructured":"Tai P, Wang J, Jin H, Song X, Yan J, Kang Y, Zhao L, An X, Du X, Chen X, Wang S, Xia G, Wang B (2008) Induction of regulatory T cells by physiological level estrogen. J Cell Physiol 214(2):456\u2013464","journal-title":"J Cell Physiol"},{"issue":"6","key":"8022_CR54","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo DG, Ruffell B (2019) Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol 19(6):369\u2013382","journal-title":"Nat Rev Immunol"},{"issue":"17","key":"8022_CR55","doi-asserted-by":"publisher","first-page":"E4041","DOI":"10.1073\/pnas.1720948115","volume":"115","author":"E Peranzoni","year":"2018","unstructured":"Peranzoni E, Lemoine J, Vimeux L, Feuillet V, Barrin S, Kantari-Mimoun C, Bercovici N, Gu\u00e9rin M, Biton J, Ouakrim H, R\u00e9gnier F, Lupo A, Alifano M, Damotte D, Donnadieu E (2018) Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti\u2013PD-1 treatment. Proc Natl Acad Sci 115(17):E4041\u2013E4050","journal-title":"Proc Natl Acad Sci"},{"key":"8022_CR56","doi-asserted-by":"publisher","first-page":"105415","DOI":"10.1016\/j.jsbmb.2019.105415","volume":"193","author":"DC M\u00e1rquez-Garb\u00e1n","year":"2019","unstructured":"M\u00e1rquez-Garb\u00e1n DC, Deng G, Comin-Anduix B, Garcia AJ, Xing Y, Chen HW, Cheung-Lau G, Hamilton N, Jung ME, Pietras RJ (2019) Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy. J Steroid Biochem Mol Biol 193:105415","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"2","key":"8022_CR57","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/imm.13627","volume":"169","author":"AD Lopes","year":"2023","unstructured":"Lopes AD, Galdino NAL, Figueiredo AB, Brianese RC, Morais KLP, De Brot M, Os\u00f3rio CABT, Teixeira-Carvalho A, Calsavara VF, Evangelista GFB, Alves NS, Makdissi FB, Sanches SM, Cordeiro de Lima VC, Carraro DM, Gollob KJ (2023) Systemic immune mediators reflect tumour-infiltrating lymphocyte intensity and predict therapeutic response in triple-negative breast cancer. Immunology 169(2):229\u2013241","journal-title":"Immunology"},{"issue":"2","key":"8022_CR58","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10549-024-07492-7","volume":"209","author":"E Ishikawa","year":"2025","unstructured":"Ishikawa E, Watanabe T, Kihara T, Kuroiwa M, Komatsu M, Urano S, Nagahashi M, Hirota S, Miyoshi Y (2025) The cytokine profile correlates with less tumor-infiltrating lymphocytes in luminal A breast cancer. Breast Cancer Res Treat 209(2):291\u2013302","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"8022_CR59","doi-asserted-by":"publisher","first-page":"4676","DOI":"10.3390\/cimb44100319","volume":"44","author":"LV Bel\u2019skaya","year":"2022","unstructured":"Bel\u2019skaya LV, Loginova AI, Sarf EA (2022) Pro-Inflammatory and Anti-Inflammatory Salivary Cytokines in Breast Cancer: Relationship with Clinicopathological Characteristics of the Tumor. Curr Issues Mol Biol 44(10):4676\u20134691","journal-title":"Curr Issues Mol Biol"},{"key":"8022_CR60","doi-asserted-by":"publisher","first-page":"p494581","DOI":"10.1155\/2014\/494581","volume":"2014","author":"XL Zhou","year":"2014","unstructured":"Zhou XL, Fan W, Yang G, Yu MX (2014) The clinical significance of PR, ER, NF- \u03ba B, and TNF- \u03b1 in breast cancer. Dis Markers 2014:p494581","journal-title":"Dis Markers"},{"key":"8022_CR61","doi-asserted-by":"crossref","unstructured":"De Cesaris, P., D. Starace, A. Riccioli, F. Padula, A. Filippini, and E. Ziparo (1998) Tumor necrosis factor-\u03b1 induces interleukin-6 production and integrin ligand expression by distinct transduction pathways*. J Biol Chem 273(13):7566\u20137571","DOI":"10.1074\/jbc.273.13.7566"},{"issue":"11","key":"8022_CR62","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/j.1745-7254.2008.00889.x","volume":"29","author":"X Wang","year":"2008","unstructured":"Wang X, Lin Y (2008) Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin 29(11):1275\u20131288","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"8022_CR63","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1177\/172460081002500302","volume":"25","author":"E Papadopoulou","year":"2010","unstructured":"Papadopoulou E, Tripsianis G, Anagnostopoulos K, Tentes I, Kakolyris S, Galazios G, Sivridis E, Simopoulos K, Kortsaris A (2010) Significance of serum tumor necrosis factor-alpha and its combination with HER-2 codon 655 polymorphism in the diagnosis and prognosis of breast cancer. Int J Biol Markers 25(3):126\u2013135","journal-title":"Int J Biol Markers"},{"issue":"3","key":"8022_CR64","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.15562\/bmj.v11i3.3611","volume":"11","author":"R Efendi","year":"2022","unstructured":"Efendi R, Ghaib H, Ali I (2022) Association between serum TNF-\u03b1 level with the incidence of metastases in women with breast cancer in Dr. Soetomo General Hospital, Indonesia. Bali Med J 11(3):1548\u20131552","journal-title":"Bali Med J"},{"key":"8022_CR65","doi-asserted-by":"publisher","first-page":"1721727X2211065","DOI":"10.1177\/1721727X221106507","volume":"20","author":"AF Gharib","year":"2022","unstructured":"Gharib AF, El Askary A, Almehmadi M, Alhuthali HM, Elsawy WH, Allam HH, Elsayyad LK, Ayoub MA, Shafie A (2022) Association of vitamin D deficiency and inflammatory cytokines with the clinicopathological features of breast cancer in female Saudi patients. Eur J Inflamm 20:1721727X221106507","journal-title":"Eur J Inflamm"},{"issue":"1","key":"8022_CR66","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1186\/s12885-022-09975-6","volume":"22","author":"E Fontvieille","year":"2022","unstructured":"Fontvieille E, His M, Biessy C, Navionis AS, Torres-Mej\u00eda G, \u00c1ngeles-Llerenas A, Alvarado-Cabrero I, S\u00e1nchez GI, Navarro E, Cortes YR, Porras C, Rodriguez AC, Garmendia ML, Soto JL, Moyano L, Porter PL, Lin MG, Guenthoer J, Romieu I, Rinaldi S (2022) Inflammatory biomarkers and risk of breast cancer among young women in Latin America: a case-control study. BMC Cancer 22(1):877","journal-title":"BMC Cancer"},{"issue":"31","key":"8022_CR67","doi-asserted-by":"publisher","first-page":"18367","DOI":"10.1074\/jbc.270.31.18367","volume":"270","author":"DI Jeoung","year":"1995","unstructured":"Jeoung DI, Tang B, Sonenberg M (1995) Effects of tumor necrosis factor-alpha on antimitogenicity and cell cycle-related proteins in MCF-7 cells. J Biol Chem 270(31):18367\u201318373","journal-title":"J Biol Chem"},{"issue":"35","key":"8022_CR68","doi-asserted-by":"publisher","first-page":"58338","DOI":"10.18632\/oncotarget.16873","volume":"8","author":"X Cai","year":"2017","unstructured":"Cai X, Cao C, Li J, Chen F, Zhang S, Liu B, Zhang W, Zhang X, Ye L (2017) Inflammatory factor TNF-\u03b1 promotes the growth of breast cancer via the positive feedback loop of TNFR1\/NF-\u03baB (and\/or p38)\/p-STAT3\/HBXIP\/TNFR1. Oncotarget 8(35):58338\u201358352","journal-title":"Oncotarget"},{"issue":"3","key":"8022_CR69","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/jcp.22264","volume":"225","author":"G Storci","year":"2010","unstructured":"Storci G, Sansone P, Mari S, D\u2019Uva G, Tavolari S, Guarnieri T, Taffurelli M, Ceccarelli C, Santini D, Chieco P, Marcu KB, Bonaf\u00e8 M (2010) TNFalpha up-regulates SLUG via the NF-kappaB\/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype. J Cell Physiol 225(3):682\u2013691","journal-title":"J Cell Physiol"},{"issue":"1","key":"8022_CR70","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1038\/s41598-020-58642-y","volume":"10","author":"W Liu","year":"2020","unstructured":"Liu W, Lu X, Shi P, Yang G, Zhou Z, Li W, Mao X, Jiang D, Chen C (2020) TNF-\u03b1 increases breast cancer stem-like cells through up-regulating TAZ expression via the non-canonical NF-\u03baB pathway. Sci Rep 10(1):1804","journal-title":"Sci Rep"},{"issue":"1","key":"8022_CR71","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3390\/ijms14010411","volume":"14","author":"V Pileczki","year":"2012","unstructured":"Pileczki V, Braicu C, D Gherman C, Berindan-Neagoe I (2012) TNF-\u03b1 gene knockout in triple negative breast cancer cell line induces apoptosis. Int J Mol Sci 14(1):411\u2013420","journal-title":"Int J Mol Sci"},{"issue":"1","key":"8022_CR72","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41420-023-01419-9","volume":"9","author":"E-G Sun","year":"2023","unstructured":"Sun E-G, Vijayan V, Park M-R, Yoo KH, Cho S-H, Bae W-K, Shim H-J, Hwang J-E, Park I-K, Chung I-J (2023) Suppression of triple-negative breast cancer aggressiveness by LGALS3BP via inhibition of the TNF-\u03b1\u2013TAK1\u2013MMP9 axis. Cell Death Discovery 9(1):122","journal-title":"Cell Death Discovery"},{"key":"8022_CR73","doi-asserted-by":"publisher","first-page":"106867","DOI":"10.1016\/j.prostaglandins.2024.106867","volume":"174","author":"Z Kavyani","year":"2024","unstructured":"Kavyani Z, Najafi K, Naghsh N, Karvane HB, Musazadeh V (2024) The effects of curcumin supplementation on biomarkers of inflammation, oxidative stress, and endothelial function: A meta-analysis of meta-analyses. Prostaglandins Other Lipid Mediat 174:106867","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"8022_CR74","doi-asserted-by":"crossref","unstructured":"Naghsh N, Musazadeh V, Nikpayam O, Kavyani Z, Moridpour AH, Golandam F, Faghfouri AH, Ostadrahimi A (2023) Profiling inflammatory biomarkers following curcumin supplementation: an umbrella meta-analysis of randomized clinical trials. Evidence-Based Complementary and Alternative Medicine 2023(1):4875636","DOI":"10.1155\/2023\/4875636"},{"issue":"10","key":"8022_CR75","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/j.numecd.2023.03.010","volume":"33","author":"B Sarmadi","year":"2023","unstructured":"Sarmadi B, Musazadeh V, Dehghan P, Karimi E (2023) The effect of cinnamon consumption on lipid profile, oxidative stress, and inflammation biomarkers in adults: An umbrella meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis 33(10):1821\u20131835","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"4","key":"8022_CR76","doi-asserted-by":"publisher","first-page":"p1111","DOI":"10.1016\/j.cell.2016.10.018","volume":"167","author":"R Ter Horst","year":"2016","unstructured":"Ter Horst R, Jaeger M, Smeekens SP, Oosting M, Swertz MA, Li Y, Kumar V, Diavatopoulos DA, Jansen AFM, Lemmers H, Toenhake-Dijkstra H, van Herwaarden AE, Janssen M, van der Molen RG, Joosten I, Sweep F, Smit JW, Netea-Maier RT, Koenders M, Xavier RJ, van der Meer JWM, Dinarello CA, Pavelka N, Wijmenga C, Notebaart RA, Joosten LAB, Netea MG (2016) Host and Environmental Factors Influencing Individual Human Cytokine Responses. Cell 167(4):p1111\u20131124e13","journal-title":"Cell"},{"key":"8022_CR77","doi-asserted-by":"publisher","first-page":"903679","DOI":"10.3389\/fimmu.2022.903679","volume":"13","author":"A Ben-Baruch","year":"2022","unstructured":"Ben-Baruch A (2022) Tumor Necrosis Factor \u03b1: Taking a Personalized Road in Cancer Therapy. Front Immunol 13:903679","journal-title":"Front Immunol"},{"issue":"49","key":"8022_CR78","doi-asserted-by":"publisher","first-page":"e40845","DOI":"10.1097\/MD.0000000000040845","volume":"103","author":"EI Obeagu","year":"2024","unstructured":"Obeagu EI, Obeagu GU (2024) Lymphocyte infiltration in breast cancer: A promising prognostic indicator. Med (Baltim) 103(49):e40845","journal-title":"Med (Baltim)"},{"key":"8022_CR79","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.humpath.2017.09.012","volume":"69","author":"K Wang","year":"2017","unstructured":"Wang K, Shen T, Siegal G, Wei S (2017) The CD4\/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer. Hum Pathol 69:110\u2013117","journal-title":"Hum Pathol"},{"key":"8022_CR80","doi-asserted-by":"crossref","unstructured":"Stanton S, Disis M (2016) Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer 4","DOI":"10.1186\/s40425-016-0165-6"},{"key":"8022_CR81","unstructured":"Fusco C, Di Rella F, Liotti A, Colamatteo A, Ferrara AL, Gigantino V, Collina F, Esposito E, Donzelli I, Porcellini A, Feola A, Micillo T, Perna F, Garziano F, Maniscalco GT, Varricchi G, Mottola M, Zuccarelli B, De Simone B, di Bonito M, Matarese G, Accurso A, Pontillo M, Russo D, Insabato L, Spaziano A, Cantone I, Pezone A, De Rosa V (11) CD4\u2009+\u2009FOXP3Exon2+ regulatory T cell frequency predicts breast cancer prognosis and survival. Sci Adv 3:peadr7934"},{"issue":"12","key":"8022_CR82","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/pin.12355","volume":"65","author":"H Ohtani","year":"2015","unstructured":"Ohtani H, Mori-Shiraishi K, Nakajima M, Ueki H (2015) Defining lymphocyte-predominant breast cancer by the proportion of lymphocyte-rich stroma and its significance in routine histopathological diagnosis. Pathol Int 65(12):644\u2013651","journal-title":"Pathol Int"},{"issue":"28","key":"8022_CR83","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1002\/sim.3944","volume":"29","author":"IR White","year":"2010","unstructured":"White IR, Carlin JB (2010) Bias and efficiency of multiple imputation compared with complete-case analysis for missing covariate values. Stat Med 29(28):2920\u20132931","journal-title":"Stat Med"},{"issue":"3","key":"8022_CR84","first-page":"209","volume":"24","author":"ID Gukas","year":"2005","unstructured":"Gukas ID, Jennings BA, Mandong BM, Igun GO, Girling AC, Manasseh AN, Ugwu BT, Leinster SJ (2005) Clinicopathological features Mol markers breast cancer Jos Nigeria West Afr J Med 24(3):209\u2013213","journal-title":"Clinicopathological features Mol markers breast cancer Jos Nigeria West Afr J Med"},{"issue":"9","key":"8022_CR85","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1093\/jnci\/86.9.705","volume":"86","author":"RM Elledge","year":"1994","unstructured":"Elledge RM, Clark GM, Chamness GC, Osborne CK (1994) Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 86(9):705\u2013712","journal-title":"J Natl Cancer Inst"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08022-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08022-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08022-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:04:23Z","timestamp":1785445463000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-08022-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["8022"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08022-3","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by Duke University and the participating hospitals\u2019 Institutional Review Boards (Pro00102004), and conducted in accordance with the Declaration of Helsinki. All participants included provided informed consent.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants included in the study provided informed consent.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"10"}}